Kathleen P. Bloch - 02 Apr 2024 Form 4 Insider Report for Cytosorbents Corp (CTSO)

Reporting relationship: Chief Financial Officer
Issuer ticker: CTSO
Reported as of: 02 Apr 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Apr 2024, 21:46:38 UTC
Prior SEC filing: 02 Apr 2024
Source filing: View source filing
Reporting owner signature: /s/ Kathleen P. Bloch

Key filing fact

Kathleen P. Bloch filed Form 4 for Cytosorbents Corp (CTSO) on 04 Apr 2024.

Key facts

This page summarizes Kathleen P. Bloch's Form 4 filing for Cytosorbents Corp (CTSO).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 04 Apr 2024, 21:46.

Change

Previous filing in this sequence was filed on 02 Apr 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CTSO transaction

Common Stock

Award

Transaction value: $0
Shares: +65,000
Change %: +14%
Price: $0.000000
Shares after: 532,941
Date: 02 Apr 2024
Ownership: Direct
Footnotes: F1, F2, F3, F4, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CTSO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +87,000
Change %
Price
Shares after: 87,000
Date: 02 Apr 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 87,000
Exercise price: $0.9550
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

These shares represent restricted stock units ("RSUs") which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

Footnote F2

Includes: (i) the following RSUs, which vest as to 10,000 RSUs on the first anniversary of the date of grant, and 10,000 RSUs on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date), and will be settled into common stock, par value $0.001 per share (the "Common Stock"), upon vesting: 20,000 RSUs granted on September 18, 2023;

Footnote F3

(continued from footnote 2) (ii) the following RSUs that will be settled into Common Stock upon a "Change In Control" of the Company, as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 8,800 RSUs granted on March 15, 2018, (b) 15,700 RSUs granted on February 24, 2017, (c) 47,000 RSUs granted on June 7, 2016 and (d) 110,000 RSUs granted on April 8, 2015;

Footnote F4

(continued from footnote 3) (iii) the following RSUs, which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into Common Stock upon vesting: 18,500 RSUs granted on August 10, 2022; and

Footnote F5

(continued from footnote 4) (iv) 247,941 shares of Common Stock owned by the reporting person.

Footnote F6

These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.